Skip to main content
Midas Edge

KORU Medical Systems, Inc.

For the period ended Dec 31, 2025. Filed Mar 12, 2026.

View on SEC.gov

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2025 · Filed Mar 12, 2026

KRMD$3.16-2.2%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits
Contents

Item 15. Exhibits and Financial Statement Schedules

All financial statement schedules have been omitted because they are not required, not applicable, not present in amounts sufficient to require submission of the schedule, or the required information is otherwise included.

The following exhibits are filed herewith or incorporated by reference as part of this Annual Report.

Exhibit No.Description
2.1Agreement and Plan of Merger by and between KORU Medical Systems, Inc., a New York corporation, and KORU Medical Systems, Inc., a Delaware corporation (incorporated by reference to our Form 8-K filed with the SEC on May 17, 2023).
3.1(i)Certificate of Incorporation of KORU Medical Systems, Inc. effective May 16, 2023 (incorporated by reference to our Form 8-K filed with the SEC on May 17, 2023).
3.1(ii)Amended and Restated By-laws of KORU Medical Systems, Inc., effective February 5, 2026 (incorporated by reference to our Form 8-K filed with the SEC on February 10, 2026).
4.1Description of Securities (incorporated by reference to the Company’s Form 10-K filed with the SEC on March 23, 2021).
10.12015 Stock Option Plan, as amended (incorporated by reference to the Company’s Proxy Statement on Schedule 14A filed with the SEC on July 28, 2016).
10.22021 Omnibus Equity Incentive Plan (incorporated by reference to the Company’s Proxy Statement on Schedule 14A filed with the SEC on April 5, 2021).
10.3Form of Non-Qualified Stock Option pursuant to the 2015 Stock Option Plan and the 2021 Omnibus Equity Incentive Plan (incorporated by reference to the Company’s Form 10-K filed with the SEC on March 23, 2021).
10.4Form of Incentive Stock Option pursuant to the 2015 Stock Option Plan and the 2021 Omnibus Equity Incentive Plan (incorporated by reference to the Company’s Form 10-K filed with the SEC on March 23, 2021).
10.52024 Omnibus Equity Incentive Plan (incorporated by reference to the Company’s Proxy Statement on Schedule 14A filed with the SEC on March 28, 2024).
10.6Long-Term Incentive Program (incorporated by reference to the Company’s Form 8-K filed with the SEC on August 21, 2024).
10.7Form of Performance Share Unit Award Agreement pursuant to the 2024 Omnibus Equity Incentive Plan.**
10.8Form of Restricted Stock Unit Award Agreement pursuant to the 2024 Omnibus Equity Incentive Plan.**
10.9Form of Non-Qualified Stock Option Award Agreement pursuant to the 2024 Omnibus Equity Incentive Plan.**
10.10Non-Employee Director Compensation (incorporated by reference to the Company’s Proxy Statement on Schedule 14A filed with the SEC on March 18, 2022).
10.11Amended and Restated Manufacturing and Supply Agreement dated as of November 17, 2025 between KORU Medical Systems, Inc. and Command Medical Products (incorporated by reference to the Company’s Form 8-K filed with the SEC on November 25, 2025). Certain information has been excluded from this exhibit because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.
10.12Employment Agreement effective as of March 15, 2021 between KORU Medical Systems, Inc. and Linda Tharby (incorporated by reference to the Company’s Form 10-K filed with the SEC on March 23, 2021).* †
10.13Amended and Restated Employment Agreement effective as of July 18, 2024 between KORU Medical Systems, Inc. and Christopher Pazdan (incorporated by reference to the Company’s Form 8-K filed with the SEC on July 24, 2024).* †
  • 52 -
Exhibit No.Description
10.14Employment Agreement effective as of October 20, 2021 between KORU Medical Systems, Inc. and Thomas Adams (incorporated by reference to the Company’s Form 10-Q filed with the SEC on August 3, 2022).*
10.15First Amendment to Employment Agreement effective as of August 1, 2023 between Thomas Adams and KORU Medical Systems, Inc. (incorporated by reference to the Company’s Form 8-K filed with the SEC on August 2, 2023).* †
10.16Employment Agreement effective as of June 30, 2025 between KORU Medical Systems, Inc. and Adam Kalbermatten (incorporated by reference to the Company’s Form 10-Q filed with the SEC on August 6, 2025).*
10.17Lease dated as of January 21, 2022 between the Company and Breit Industrial Canyon NJ1W05 LLC (incorporated by reference to the Company’s Form 10-K filed with the SEC on March 2, 2022).
10.18Loan and Security Agreement dated as of March 8, 2024 by and between KORU Medical Systems, Inc. and HSBC Ventures USA Inc. (incorporated by reference to the Company’s Form 8-K filed with the SEC on March 13, 2024).+
10.19Stock Purchase Warrant issued to HSBC Ventures USA Inc. issued on March 8, 2024 (incorporated by reference to the Company’s Form 8-K filed with the SEC on March 13, 2024).
19KORU Medical Systems, Inc. Amended and Restated Insider Trading Policy.**
23.1Consent of Cherry Bekaert LLP.**
24.1Power of Attorney (included on the signature pages hereto)
31.1Certification of the Principal Executive Officer of registrant required under Section 302 of the Sarbanes-Oxley Act of 2002.**
31.2Certification of the Principal Financial Officer of registrant required under Section 302 of the Sarbanes-Oxley Act of 2002.**
32.1Certification of the Principal Executive Officer of registrant required under Section 906 of the Sarbanes-Oxley Act of 2002.**
32.2Certification of the Principal Financial Officer of registrant required under Section 906 of the Sarbanes-Oxley Act of 2002.**
97Clawback Policy (incorporated by reference to the Company’s Form 10-K filed with the SEC on March 12, 2025).
101.INSInline XBRL Instance Document - the XBRL Instance Document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document.
101.SCHInline XBRL Taxonomy Extension Schema Document.
101.CALInline XBRL Taxonomy Extension Calculation Linkbase Document.
101.DEFInline XBRL Taxonomy Definition Linkbase Document.
101.LABInline XBRL Taxonomy Extension Label Linkbase Document.
101.PREInline XBRL Taxonomy Extension Presentation Linkbase Document.
+Certain schedules, appendices and/or exhibits to this agreement have been omitted in accordance with Item 601 of Regulation S-K. A copy of any omitted schedule and/or exhibit will be furnished supplementally to the Securities and Exchange Commission staff upon request.
*Denotes management compensatory agreement or arrangement.
†Certain information has been omitted from this exhibit because it is not material and would be competitively harmful if publicly disclosed.
**Filed herewith.
ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.